The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states

American Journal of Kidney Diseases

Volumn 28, Issue 2, 1996, Pages 235-249

  Thamer, Mae ^a   Richard, Christian ^b   Ray, Nancy Fox ^b   Greer, Joel W ^b   Cotter, Dennis J ^b   Pearson, Brian C ^b  

^a Med Technol Pract Patterns Inst   (United States)

^b NONE

Author keywords

Anemia; end stage renal disease; hematocrit levels; insurance status; Medicaid coverage; recombinant human erythropoietin

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CHILD; CHRONIC KIDNEY FAILURE; COST CONTROL; FEMALE; HEALTH CARE UTILIZATION; HEMATOCRIT; HEMODIALYSIS; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; REIMBURSEMENT; TREATMENT OUTCOME;

EID: 0029817533     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(96)90307-8     Document Type: Article

References (42)

1. Eschbach JW, Egrie JC, Downing MR, Adamson JW: Correction of the anemia of end stage renal disease with recombinant human erythropoietin. N Engl J Med 316:73-78, 1987
2. Eschbach JW: The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 35:134-138, 1989
3. Guthrie M, Cardenas D, Eschbach JW, Haley NR, Robertson HT, Evans RW: Effect of erythropoietin on strength and functional status of patients on hemodialysis. Clin Nephrol 39:97-102, 1993
4. Delano BG: Improvements in quality of life following treatment with rHuEPO in anemic hemodialysis patients. Am J Kidney Dis 14:14-18, 1989 (suppl)
5. Powe NR, Griffiths RI, Anderson GF, de Lissovoy G, Watson AJ, Greer JW, Herbert RJ, Whelton PK: Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients. Am J Kidney Dis 22:557-567, 1993
6. Powe NR, Griffiths RI, de Lissovoy G, Anderson GF, Watson AJ, Greer JW, Herbert RJ, Eggers PW, Milam RA, Whelton PK: Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval. JAMA 268:1434-1440, 1992
7. Petronis KR, Carrol CE, Held PJ, Port FK: Effect of race on access to recombinant human erythropoietin in long-term hemodialysis patients. JAMA 271:1760-1763, 1994
8. Sisk JE, Gianfrancesco FD, Coster JM: Recombinant erythropoietin and Medicare payment. JAMA 266:247-252, 1991
9. Health Care Financing Administration: Health Care Financing Research Report: End Stage Renal Disease, 1991. May 1993, Health Care Financing Administration, Pub 03338
10. Wolfson M, Mundt DJ, Hawley GG: Recombinant human erythropoietin utilization in the Department of Veterans Affairs dialysis units. Am J Kidney Dis 24:184-191, 1994
11. Rettig RA, Levinsky NG (eds): Institute of Medicine: Kidney Failure and the Federal Government. Washington, DC, National Academy Press, 1991
12. Thamer M, Ray NF, Richard C, Greer JW, Pearson BC, Cotter D: Excluded from 'universal' coverage: End-stage renal disease patients not covered by Medicare. Health Care Fin Rev 17:123-146, 1995
13. Rowland D, Salganicoff A: Commentary: Lessons from Medicaid - Improving access to office-based physician care for the low-income population. Am J Public Health 84:550-552, 1994
14. The Medicaid Access Study Group: Access of Medicaid recipients to outpatient care. N Engl J Med 330:1426-1430, 1994
15. St Peter RF, Newacheck PW, Halfen N: Access to care for poor children: Separate but equal? JAMA 267:2760-2764, 1992
16. Bloom BS, Fox NA, Jacobs J: Patterns of care and expenditures by California Medicaid for peptic ulcer and other acid-related diseases. J Clin Gastroenterol 11:615-620, 1989
17. Fox ML, Weiner JP, Phua K: Effect of Medicaid payment levels on access to obstetrical care. Health Affairs 11:150-161, 1992
18. Gondek K: Prescription drug payment policy: Past, present and future. Health Care Financ Rev 15:1-7, 1994
19. Medical Technology and Practice Patterns Institute: Survey of State Medicaid Programs Regarding Initial Month of EPO Coverage. Washington, DC, Medical Technology and Practice Patterns Institute, 1992
20. United States Renal Data System: USRDS 1993 Annual Data Report. Bethesda, MD, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1993
21. Thamer M, Ray NF, Fehrenbach SN, Richard C, Kimmel P: Relative risk and economic consequences of inpatient care among patients with renal failure. J Am Soc Nephrol 7:751-762, 1996
22. Heckman J: Sample selection bias as a specification error. Econometrica 47:153-161, 1979
23. Lee L: Generalized models with selectivity. Econometrica 51:507-512, 1983
24. Health Care Financing Administration: 1994 ESRD Core Indicators Project, December 1994
25. Philip J. Held, Director, United States Renal Data System, March 15, 1996, personal communications
26. Health Care Financing Administration and the National Association of Insurance Commissioners: 1995 Guide to Health Insurance for People with Medicare. Publication no. HCFA-02110, January 1995
27. G. Hankla, Pharmacist, Georgia Department of Medical Assistance; M. Neff, Medical Contracting Specialist, California Medi-Cal Program; and S. Klein, Policy Analyst, Michigan Department of Social Services; December 1995, personal communications
28. Buchanan RJ, Smith SR: Medicaid policies for HIV-related prescription drugs. Health Care Financ Rev 15:43-61, 1994
29. Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S: Payment restrictions for prescription drugs under Medicaid. N Engl J Med 317:550-556, 1989
30. Smith DG: The effects of copayments and generic substitution on the use and costs of prescription drugs. Inquiry 30:189-198, 1993
31. Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin TJ, Choodnovskiy I: Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med 325:1072-1077, 1991
32. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P: Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 331:650-655, 1994
33. Newhouse JP, Manning WG, Morris CN, Orr LL, Duan N, Keeler EB, Leibowitz A, Marquis KH, Marquis MS, Phelps CE, Brook RH: Some interim results from a controlled trial of cost sharing in health insurance. N Engl J Med 305:1501-1507, 1981
34. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, Korbet S, Krantz SB, Lundin AP, Nissenson AR, Ogden DA, Paganini EP, Rader B, Rutsky EA, Stivelman J, Stone WJ, Teschan P, Van Stone JC, Van Wyck DB, Zuckerman K, Adamson JW: Recombinant human erythropoietin in anemic patients with end-stage renal disease. Ann Intern Med 111:992-1000, 1989
35. Powe NR, Griffiths RI, Greer JW, Greer JW, Watson AJ, Anderson GF, De Lissovoy G, Herbert RJ, Eggers PW, Milam RA, Whelton PK: Early dosing practices and effectiveness of recombinant human erythropoietin. Kidney Int 43:1125-1133, 1993
36. Ifudu O, Mayers J, Mathew J, Tan CC, Cambridge A, Friedman EA: Dismal rehabilitation in geriatric inner-city hemodialysis patients. JAMA 271:29-33, 1994
37. Ifudu O, Feldman J, Friedman EA: The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 334:420-425, 1996
38. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78, 1987
39. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, Korbet S, Krantz SB, Lundin AP, Nissenson AR, Ogden DA, Paganini EP, Rader B, Rutsky EA, Stivelman J, Stone WJ, Teschan P, Van Stone JC, Van Wyck DB, Zuckerman K, Adamson JW: Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter clinical trial. Ann Intern Med 111:992-1000, 1989
40. Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA: Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 35:712-716, 1989
41. Rakel RE (ed): Conn's Current Therapy, 1995. Philadelphia, PA, Saunders, 1995
42. Stein JH (ed): Internal Medicine (ed 4). St Louis, MO, Mosby, 1994